| 2026-08-06 | Press release | Ocugen Provides Business Update with Second Quarter 2026 Financial Results |
| 2026-07-31 | Press release | Ocugen to Participate in Upcoming August Investor Conferences |
| 2026-07-29 | Press release | Ocugen Announces that the U.S. Food and Drug Administration Has Granted OCU410 Regenerative Medicine Advanced Therapy (R |
| 2026-07-13 | Press release | Ocugen, Inc. Announces Binding Term Sheet with Roots Pharmaceutical to License OCU400 Modifier Gene Therapy for Retiniti |
| 2026-07-01 | Press release | Ocugen to Participate in Upcoming July Industry Conferences |
| 2026-06-02 | Press release | Ocugen to Participate in Upcoming June Investor and Industry Conferences |
| 2026-05-14 | Press release | Ocugen, Inc. Announces Closing for $130.0 Million of 6.75% Convertible Senior Notes |
| 2026-05-13 | Press release | Ocugen to Participate in Upcoming May Scientific and Investor Conferences |
| 2026-05-05 | Press release | Ocugen, Inc. Announces Pricing of $115 Million of 6.75% Convertible Senior Notes |
| 2026-05-04 | Press release | Ocugen Announces Private Offering of $115 Million of Convertible Senior Notes |
| 2026-04-23 | Press release | Ocugen to Present at April 2026 Investor and Industry Conferences |
| 2026-04-01 | Press release | Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease |
| 2026-03-24 | Press release | Ocugen Announces Topline 12-month Data from Phase 2 ArMaDa Clinical Trial Evaluating OCU410 Modifier Gene Therapy for Ge |
| 2026-03-23 | Press release | Ocugen to Host Webcast on Tuesday, March 24 at 8 a.m. EDT to Discuss Phase 2 Clinical Trial Data for OCU410—Modifier Gen |
| 2026-03-04 | Press release | Ocugen Provides Business Update with Fourth Quarter and Full Year 2025 Financial Results |
| 2026-03-02 | Press release | Press release |
| 2026-03-02 | Press release | Ocugen Announces Phase 3 liMeliGhT Enrollment Completion for OCU400, a Novel Modifier Gene Therapy for Broad Retinitis P |
| 2026-02-18 | Press release | Press release |
| 2026-02-18 | Press release | Ocugen to Host Conference Call on Wednesday, March 4, 2026 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarte |
| 2026-02-09 | Press release | Press release |
| 2026-02-09 | Press release | Ocugen Appoints Rita Johnson-Greene to Chief Financial Officer |
| 2026-01-23 | Press release | Press release |
| 2026-01-23 | Press release | Ocugen, Inc. Announces Closing of $22.5 Million Underwritten Registered Direct Offering of Common Stock |
| 2026-01-21 | Press release | Press release |
| 2026-01-21 | Press release | Ocugen, Inc. Announces Pricing of $22.5 Million Offering of Common Stock |
| 2026-01-15 | Press release | Press release |
| 2026-01-15 | Press release | Ocugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to |
| 2026-01-13 | Press release | Press release |
| 2026-01-13 | Press release | Ocugen to Host Webcast on Thursday, January 15 at 8:30 a.m. ET to Discuss OCU410 Phase 2 Clinical Trial Data |
| 2026-01-12 | Press release | Press release |
| 2026-01-12 | Press release | Ocugen Announces Publication of Phase 1 GARDian1 Trial Results for OCU410ST Modifier Gene Therapy |
| 2026-01-12 | Press release | Page 3 |
| 2026-01-09 | Press release | Press release |
| 2026-01-09 | Press release | Ocugen CEO to Present at J.P. Morgan 2026 Healthcare Conference |
| 2025-12-10 | Press release | Press release |
| 2025-11-20 | Press release | Press release |
| 2025-10-23 | Press release | Press release |
| 2025-10-02 | Press release | Press release |
| 2025-09-15 | Press release | Press release |
| 2025-09-02 | Press release | Press release |